Sellas Life Sciences
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Sellas Life Sciences (SLS) | 2.78B | -68.30 | 21.11 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 19.6% above Morningstar's fair value estimate.
Fair value
SELLAS Life Sciences Group Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 28% discount to our quantitative fair value estimate of $10.99 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's liquidity increases our valuation estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days ranks in the top 20% compared with peers globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.
Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.3%, a core component of profitability, ranks in the bottom 30% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:58:45 · For reference only, not investment advice and not tailored to your situation.
Sellas Life Sciences discussion 0 comments